Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | nitric oxide synthase, putative | 0.0814 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0814 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0814 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0814 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0814 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0814 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0814 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0814 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0814 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0814 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0814 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0814 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0814 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0814 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0814 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0404 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0814 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0814 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0722 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0814 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0503 | 0.2407 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0814 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0503 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0814 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0404 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0722 | 0.7743 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0814 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0814 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.041 | 0.0151 | 0.0151 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibitory potency (binding) | = 0.04 | Ratio of Km(ADP)/Ki or Km for rat liver pyruvate kinase | ChEMBL. | 7143354 |
Inhibitory potency (binding) | = 0.1 | Ratio of Km(ADP)/Ki or Km for rat kidney pyruvate kinase (PK-K) | ChEMBL. | 7143354 |
Inhibitory potency (binding) | = 0.12 | Ratio of Km(ADP)/Ki or Km for rat muscle pyruvate kinase | ChEMBL. | 7143354 |
Ki (binding) | = 4.3 mM | Inhibition of rat muscle pyruvate kinase (PK-M) | ChEMBL. | 7143354 |
Ki (binding) | = 5 mM | Inhibition of rat kidney pyruvate kinase (PK-K) | ChEMBL. | 7143354 |
Ki (binding) | = 7.5 mM | Inhibitory constant for inhibition of pyruvate kinase obtained from rat liver (PK-L) was determined using ADP as competitive inhibitor | ChEMBL. | 7143354 |
Relative inhibitory potency (binding) | = 2.5 | Relative inhibitory potency as ratio of kidney and liver pyruvate kinases | ChEMBL. | 7143354 |
Relative inhibitory potency (binding) | = 3 | Relative inhibitory potency as ratio of muscle and liver pyruvate kinases | ChEMBL. | 7143354 |
Relative Vmax (binding) | = 0 | Relative half maximal velocity of Pyruvate kinase and Phosphoenolpyruvate | ChEMBL. | 7143354 |
Relative Vmax (binding) | = 0 | Relative half maximal velocity of Pyruvate kinase to Phosphoenolpyruvate was determined | ChEMBL. | 7143354 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.